News Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 10:24:28 2024-06-05 am EDT			5-day change	1st Jan Change
3 ^ILa	+7.14%		+7.14%	+15.38%

Jun. 05	Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study	CI
May. 12	Transcript : Can-Fite BioPharma Ltd. - Special Call

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study	Jun. 05	BU
Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study	Jun. 05	CI
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases	May. 29	BU
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024	May. 27	BU
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6	May. 23	BU
Can Fite BioPharma : Immediate Report of Meeting	May. 22	PU
Can Fite BioPharma : NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K	May. 22	PU
Can Fite BioPharma : Immediate Report	May. 13	PU
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study	May. 13	BU
Transcript : Can-Fite BioPharma Ltd. - Special Call	May. 11
CAN-FITE, FDA GRANTS IND CLEARANCE FOR NAMODENOSON TO TREAT MASH PATIENTS IN A PHASE IIB STUDY	May. 10	AQ
Can Fite BioPharma : FDA grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	May. 09	PU
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	May. 09	BU
Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	May. 09	CI
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	May. 06	BU
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	May. 06	CI
LONG-TERM COMPLETE RESPONSE TO CAN-FITE'S NAMODENOSON IN PATIENT WITH ADVANCED LIVER CANCER ARTICLE PUBLISHED IN A LEADING SCIENTIFIC JOURNAL	Apr. 26	AQ
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal	Apr. 25	BU
CAN-FITE, SCIENTIFIC ARTICLE PUBLISHED BY KOL PRESENTS NAMODENOSON AS A PROMISING DRUG CANDIDATE TO TREAT ADVANCED LIVER CANCER AND MASH	Apr. 16	AQ
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	Apr. 15	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Summary

Filters